|9th December 2020||Matthew L Sherman||207||Exercise of derivative||$34.43||$7,127.01|
|1st December 2020||Michael Douglas Taylor||11,309||Open or private sale||$61.16||$691,692.37|
|1st December 2020||Michael Douglas Taylor||1,011||Open or private sale||$61.87||$62,546.83|
|1st December 2020||Michael Douglas Taylor||200||Open or private sale||$62.94||$12,588.00|
|1st December 2020||Michael Douglas Taylor||19,000||Exercise of derivative||$1.89||$35,910.00|
|1st December 2020||Michael Douglas Taylor||6,480||Open or private sale||$60.23||$390,315.02|
|4th November 2020||Michael Douglas Taylor||15,000||Exercise of derivative||$1.89||$28,350.00|
|4th November 2020||Michael Douglas Taylor||12,169||Open or private sale||$64.67||$786,953.41|
|4th November 2020||Michael Douglas Taylor||2,831||Open or private sale||$65.36||$185,033.59|
|2nd November 2020||Michael Douglas Taylor||23,315||Exercise of derivative||$1.89||$44,065.35|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.